What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Eugenio Fiorentino, Antonio Russo, Massimo Cajozzo, Sergio Rizzo, Giuseppe Bronte, Christian Diego Rolfo, Francesco Passiglia, Christian Rolfo, Jan P. Van Meerbeeck, Cosimo Lequaglie, Daniele Santini, Ignacio Gil-Bazo, Patrick Pauwels

Risultato della ricerca: Article

15 Citazioni (Scopus)

Abstract

Background Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities. Results Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group. Conclusion This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
Lingua originaleEnglish
pagine (da-a)306-317
Numero di pagine12
RivistaCRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY
Volume95
Stato di pubblicazionePublished - 2015

Fingerprint

Platinum
Meta-Analysis
Survival Rate
Therapeutics
Safety
Population

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cita questo

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. / Fiorentino, Eugenio; Russo, Antonio; Cajozzo, Massimo; Rizzo, Sergio; Bronte, Giuseppe; Rolfo, Christian Diego; Passiglia, Francesco; Rolfo, Christian; Van Meerbeeck, Jan P.; Lequaglie, Cosimo; Santini, Daniele; Gil-Bazo, Ignacio; Pauwels, Patrick.

In: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, Vol. 95, 2015, pag. 306-317.

Risultato della ricerca: Article

@article{8b8b1b11865e4312b608782c0b1a6f9e,
title = "What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis",
abstract = "Background Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities. Results Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95{\%} CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95{\%} CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group. Conclusion This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.",
author = "Eugenio Fiorentino and Antonio Russo and Massimo Cajozzo and Sergio Rizzo and Giuseppe Bronte and Rolfo, {Christian Diego} and Francesco Passiglia and Christian Rolfo and {Van Meerbeeck}, {Jan P.} and Cosimo Lequaglie and Daniele Santini and Ignacio Gil-Bazo and Patrick Pauwels",
year = "2015",
language = "English",
volume = "95",
pages = "306--317",
journal = "CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY",
issn = "1879-0461",

}

TY - JOUR

T1 - What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

AU - Fiorentino, Eugenio

AU - Russo, Antonio

AU - Cajozzo, Massimo

AU - Rizzo, Sergio

AU - Bronte, Giuseppe

AU - Rolfo, Christian Diego

AU - Passiglia, Francesco

AU - Rolfo, Christian

AU - Van Meerbeeck, Jan P.

AU - Lequaglie, Cosimo

AU - Santini, Daniele

AU - Gil-Bazo, Ignacio

AU - Pauwels, Patrick

PY - 2015

Y1 - 2015

N2 - Background Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities. Results Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group. Conclusion This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.

AB - Background Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients. Materials and methods Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities. Results Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group. Conclusion This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.

UR - http://hdl.handle.net/10447/157384

M3 - Article

VL - 95

SP - 306

EP - 317

JO - CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY

JF - CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY

SN - 1879-0461

ER -